Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received a consensus rating of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $5.67.

A number of brokerages have issued reports on SGMO. StockNews.com initiated coverage on shares of Sangamo Therapeutics in a research note on Saturday. They set a “sell” rating on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price (up previously from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $0.52 on Tuesday. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.67. The firm’s 50 day moving average is $0.76 and its 200-day moving average is $0.59. The stock has a market capitalization of $108.38 million, a PE ratio of -0.36 and a beta of 1.39.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. Equities research analysts predict that Sangamo Therapeutics will post -0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Wasatch Advisors LP increased its stake in shares of Sangamo Therapeutics by 62.4% in the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after buying an additional 7,734,400 shares during the period. Golden State Equity Partners increased its position in Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 34,960 shares during the period. Mackenzie Financial Corp raised its stake in shares of Sangamo Therapeutics by 72.4% during the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 31,003 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Sangamo Therapeutics by 14.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 129,811 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Sangamo Therapeutics by 103.9% in the fourth quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 92,002 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.